Hikma has strengthened its partnership with UK-based Arecor, signing a second agreement to co-develop an undisclosed, ready-to-use injectable to be filed through the US Food and Drug Administration’s 505(b)(2) hybrid regulatory pathway.
Under the terms of the royalty-based agreement, Arecor will receive an upfront payment and further payments on the achievement of...





